219 related articles for article (PubMed ID: 37326143)
21. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment.
Liu YT; Tseng TC; Soong RS; Peng CY; Cheng YH; Huang SF; Chuang TH; Kao JH; Huang LR
J Immunother Cancer; 2018 Dec; 6(1):144. PubMed ID: 30526672
[TBL] [Abstract][Full Text] [Related]
22. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
[TBL] [Abstract][Full Text] [Related]
23. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.
Tao H; Liu M; Wang Y; Luo S; Xu Y; Ye B; Zheng L; Meng K; Li L
Front Immunol; 2021; 12():609295. PubMed ID: 33717093
[TBL] [Abstract][Full Text] [Related]
24. A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration.
Long M; Zhou Z; Wei X; Lin Q; Qiu M; Zhou Y; Chen P; Jiang Y; Wen Q; Liu Y; Li R; Zhou X; Yu H
Front Immunol; 2022; 13():1023349. PubMed ID: 36353638
[TBL] [Abstract][Full Text] [Related]
25. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients.
Elwan N; Salem ML; Kobtan A; El-Kalla F; Mansour L; Yousef M; Al-Sabbagh A; Zidan AA; Abd-Elsalam S
Immunol Invest; 2018 Feb; 47(2):169-180. PubMed ID: 29182438
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
[TBL] [Abstract][Full Text] [Related]
27. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.
Hetta HF; Zahran AM; Mansor SG; Abdel-Malek MO; Mekky MA; Abbas WA
J Med Virol; 2019 Jul; 91(7):1319-1328. PubMed ID: 30761547
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of SLCO4C1 as a biological marker in hepatocellular carcinoma based on anoikis classification features.
Wang T; Guo K; Yang S; Zhang D; Cui H; Yin J; Yuan S; Wang Y; Qi Y; Wu W
Aging (Albany NY); 2024 Jan; 16(2):1440-1462. PubMed ID: 38226966
[TBL] [Abstract][Full Text] [Related]
31. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
[TBL] [Abstract][Full Text] [Related]
32. Survivin (BIRC5) cell cycle computational network in human no-tumor hepatitis/cirrhosis and hepatocellular carcinoma transformation.
Wang L; Huang J; Jiang M; Sun L
J Cell Biochem; 2011 May; 112(5):1286-94. PubMed ID: 21312234
[TBL] [Abstract][Full Text] [Related]
33. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.
Shen B; Zhang G; Liu Y; Wang J; Jiang J
Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292719
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
35. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
36. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.
Kalathil S; Lugade AA; Miller A; Iyer R; Thanavala Y
Cancer Res; 2013 Apr; 73(8):2435-44. PubMed ID: 23423978
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes.
Wang Y; Zhang T; Sun M; Ji X; Xie M; Huang W; Xia L
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680276
[TBL] [Abstract][Full Text] [Related]
38. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.
Xu Y; Liao W; Luo Q; Yang D; Pan M
Front Immunol; 2022; 13():761046. PubMed ID: 35145517
[TBL] [Abstract][Full Text] [Related]
39. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
40. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
